Crizotinib Intermediate CAS 877399-00-3 Maʻemaʻe ≥98.0% (HPLC) ee ≥99.0%
ʻO Shanghai Ruifu Chemical Co., Ltd. ka mea hana nui o (R)-5-Bromo-3-[1-(2,6-Dichloro-3-Fluorophenyl)ethoxy]pyridin-2-Amine (CAS: 877399-00 -3) me ke kūlana kiʻekiʻe, waena o Crizotinib (CAS: 877399-52-5).Hiki iā Ruifu Chemical ke hāʻawi aku i ka honua holoʻokoʻa, ke kumukūʻai hoʻokūkū, ka lawelawe maikaʻi loa, ka liʻiliʻi a me ka nui nui i loaʻa.Kūʻai Crizotinib Intermediate,Please contact: alvin@ruifuchem.com
| Inoa Kimia | (R)-5-Bromo-3-[1-(2,6-Dichloro-3-Fluorophenyl)ethoxy]pyridin-2-Amine |
| Nā huaʻōlelo like | Crizotinib Intermediate;Crizotinib Bromide haumia;5-Bromo-3-[(1R)-1-(2,6-Dichloro-3-Fluorophenyl)ethoxy]-2-Pyridinamine;[5-Bromo-3-[(1R)-(2,6-Dichloro-3-Fluorophenyl)ethoxy]pyridin-2-yl]amine |
| Kūlana Kūʻai | Ma ke Kahua, Hana Hana Kūʻai |
| Helu CAS | 877399-00-3 |
| ʻĀpana Molekala | C13H10BrCl2FN2O |
| Kaumaha Molecular | 380.04 g/mol |
| Lae hehee | 108.0 a 113.0 ℃ |
| ʻO ka mānoanoa | 1.643 |
| COA & MSDS | Loaʻa |
| Laʻana | Loaʻa |
| Ke kumu | Shanghai, Kina |
| Māhele | Kūwaena o Crizotinib (CAS: 877399-52-5) |
| Brand | Kemika Ruifu |
| Nā mea | Nā Kūlana Nānā | Nā hualoaʻa |
| Ka nana aku | Melemele māmā i ka pauda melemele i ke aniani | Hoʻokō |
| Lae hehee | 108.0 a 113.0 ℃ | Hoʻokō |
| Maʻemaʻe (HPLC Area) | ≥98.0% | 99.1% |
| Enantiomeric Excess (EE) | ≥99.0% | 99.5% |
| Infrared Spectrum | Kūlike i ka hoʻolālā | Hoʻokō |
| 1 H NMR Spectrum | Kūlike i ka hoʻolālā | Hoʻokō |
| Ka hopena | Ua hoʻāʻo ʻia kēia huahana a hoʻokō i nā kikoʻī | |
| Ola Pahu | 2 makahiki inā mālama pono ʻia | |
Pūʻolo:ʻO ka ʻōmole, ʻeke ʻeke alumini, 25kg / pahu pahu pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E hoʻopaʻa paʻa i ka pahu a mālama i loko o kahi hale kūʻai maloʻo a maloʻo (2 ~ 8 ℃) a me kahi hale kūʻai maikaʻi mai nā mea like ʻole.E pale i ka malamalama a me ka wai.
Hoʻouna:Hāʻawi i ka honua ma ka lewa, e FedEx / DHL Express.Hāʻawi wikiwiki a hilinaʻi hoʻi.
Pehea e kūʻai ai?E ʻoluʻolu e kelepona maiDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 mau makahiki ʻike?Loaʻa iā mākou ma mua o 15 mau makahiki o ka ʻike i ka hana ʻana a me ka hoʻokuʻu ʻana aku i kahi ākea ākea o nā intermediates pharmaceutical kiʻekiʻe a i ʻole nā kemika maikaʻi.
Mākeke Nui?E kūʻai aku i ka mākeke kūloko, ʻAmelika ʻĀkau, ʻEulopa, India, Korea, Iapana, Australia, etc.
Nā pono?ʻO ke kūlana kiʻekiʻe, ke kumukūʻai kūpono, nā lawelawe ʻoihana a me ke kākoʻo ʻenehana, ka lawe wikiwiki ʻana.
ʻAno maikaʻiHōʻoiaʻiʻo?Pūnaehana hoʻomalu maikaʻi koʻikoʻi.ʻO nā lako ʻoihana no ka nānā ʻana ʻo NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Nā laʻana?Hāʻawi ka hapa nui o nā huahana i nā laʻana manuahi no ka loiloi maikaʻi, pono e uku ʻia ke kumukūʻai e nā mea kūʻai aku.
Hooia Hale Hana?Welina mai ka loiloi hale hana.E ʻoluʻolu e hoʻopaʻa manawa ma mua.
MOQ?ʻAʻohe MOQ.ʻAe ʻia ke kauoha liʻiliʻi.
Manawa Hoʻouna? Inā i loko o ka waihona, ʻekolu lā hoʻouna ʻia.
Kaʻahele?Ma ka Express (FedEx, DHL), ma ka Air, ma ke Kai.
Nā palapala?Ma hope o ka lawelawe kūʻai: COA, MOA, ROS, MSDS, etc.
Hoʻohui Kuʻuna?Hiki ke hāʻawi i nā lawelawe synthesis maʻamau e kūpono i kāu mau pono noiʻi.
Kūkākūkā uku?E hoʻouna mua ʻia ka invoice Proforma ma hope o ka hōʻoia ʻana o ke kauoha, hoʻopili ʻia kā mākou ʻike panakō.Uku e T/T (Telex Transfer), PayPal, Western Union, etc.
(R)-5-Bromo-3-[1-(2,6-Dichloro-3-Fluorophenyl)ethoxy]pyridin-2-Amine (CAS: 877399-00-3) hoʻohana ʻia ma ke ʻano he waena o Crizotinib (CAS: 877399-52-5).
ʻO Crizotinib kahi lāʻau anti-cancer i lilo i alk (anaplastic lymphoma kinase) a me ros1 (c-ros oncogene 1) inhibitor, i ʻae ʻia no ka mālama ʻana i kekahi maʻi carcinoma pūpū liʻiliʻi liʻiliʻi (NSCLC) ma ʻAmelika a me kekahi mau ʻāina ʻē aʻe. ke ho'āʻo nei i nā haʻawina he nui e hoʻāʻo ana i kona palekana a me ka maikaʻi ma anaplastic large cell lymphoma, neuroblastoma, a me nā maʻi maʻi paʻa kiʻekiʻe i nā pākeke a me nā keiki.
ʻO Crizotinib kahi lāʻau lapaʻau i hoʻopaʻa ʻia no ka maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi i hoʻomohala ʻia e Pfizer, USA, ʻo secorri kahi lāʻau lapaʻau mua a me ka wā e hana ai i ka lāʻau lapaʻau i kuhikuhi ʻia no ka maʻi kanesa.Ua ʻae ʻia no ke kūʻai aku ʻana ma ʻAmelika Hui Pū ʻIa i ʻAukake 2011 a ua kākau ʻia i loko o nā alakaʻi lapaʻau maʻi maʻi maʻi maʻi maʻi āpau ma ka hopena o ka makahiki ma ke ʻano he lāʻau lapaʻau mua no nā maʻi maʻi ALK.ʻO ka hui pū ʻana me Crizotinib ʻo ia ke ʻano maʻi genetic mua me ka hoʻohana ʻana i ka fluorescence in situ hybridization (FISH) -VSIs ALK Break Apart FISH Probe Kit, ʻo ia ke ʻano i hoʻohana ʻia i kēia manawa i nā hoʻokolohua lapaʻau honua e ʻike i nā genes fusion EML4-ALK i NSCLC.E kōkua ana kēia ho'āʻo e ʻike i nā poʻe maʻi e pōmaikaʻi mai ka mālama ʻana iā Crizotinib.
ʻO Crizotinib kahi mea hoʻopaneʻe koho tyrosine kinase i hoʻohana ʻia i ka lāʻau lapaʻau o nā hihia i koho ʻia o ka maʻi maʻi ʻaʻai ʻāʻī liʻiliʻi liʻiliʻi.He mea hoʻokūkū hoʻokūkū ʻelua ATP ia o tyrosine kinases c-MET (Mesenchymal-Epithelial Transition Factor) kinase (cellular IC50=8 nM) a me ALK (cellular IC50=20 nM), ʻo ia mau mea ʻelua mau pahuhopu nui no ka chemotherapy maʻi maʻi.I ka wā i hoʻāʻo ʻia ai ʻo Crizotinib no ke koho ʻana me nā kinases ʻē aʻe, ua ʻike ʻia aia nā enzyme IC50 i loko o 100-fold multiples o c-MET no 13 o nā kinase 120 i hoʻāʻo ʻia.I loko o ka cellular assays, ua ʻike ʻia ʻo Crizotinib e kāohi i ka RON (recepteur d'origine nantais) kinase me kahi puka koho koho 10-fold ma luna o c-MET.ʻO ka mea holoʻokoʻa, ke kāohi nei kēia mea hana i ka ulu ʻana o nā cell tumor.ʻO XALKORI®(Crizotinib) kahi lāʻau lapaʻau i hoʻohana ʻia no ka mālama ʻana i ka poʻe me ka maʻi maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi liʻiliʻi (NSCLC) i laha i nā ʻāpana ʻē aʻe o ke kino a ke kumu ʻia e kahi kīnā i kekahi gene i kapa ʻia ʻo ALK (anaplastic lymphoma kinase) a i ʻole. he gene i kapaia ROS1.ʻAʻole ʻike ʻia inā palekana a maikaʻi ʻo XALKORI i nā keiki.
